Evidence map›Paper›PMID 37353585›Full record

ArticleMolecular psychiatry2023

Alprazolam modulates persistence energy during emotion processing in first-degree relatives of individuals with schizophrenia: a network control study.

Arun S Mahadevan, Eli J Cornblath, David M Lydon-Staley, Dale Zhou, Linden Parkes, Bart Larsen, Azeez Adebimpe, Ari E Kahn, Ruben C Gur, Raquel E Gur and 3 more

Open access · hybridAbstract read
In one paragraph

Article in Molecular psychiatry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Controlling the human connectome with spatially diffuse input signals.bioRxiv : the preprint server for biology · 2024
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Arun S MahadevanDepartment of Bioengineering, School of Engineering & Applied Science, University of Pennsylvania, Philadelphia, PA, 19104, USA.ORCID 0000-0001-7315-8261
Eli J CornblathDepartment of Bioengineering, School of Engineering & Applied Science, University of Pennsylvania, Philadelphia, PA, 19104, USA.ORCID 0000-0002-2619-8778
David M Lydon-StaleyDepartment of Bioengineering, School of Engineering & Applied Science, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Dale ZhouDepartment of Neuroscience, Perelman School of Medicine, University of Pennsylvania, Pennsylvania, PA, 19104, USA.ORCID 0000-0001-9240-1327
Linden ParkesDepartment of Bioengineering, School of Engineering & Applied Science, University of Pennsylvania, Philadelphia, PA, 19104, USA.ORCID 0000-0002-9329-7207
Bart LarsenDepartment of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Azeez AdebimpeDepartment of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.ORCID 0000-0001-9049-0135
Ari E KahnDepartment of Bioengineering, School of Engineering & Applied Science, University of Pennsylvania, Philadelphia, PA, 19104, USA.ORCID 0000-0002-2127-0507
Ruben C GurDepartment of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.ORCID 0000-0002-4082-8502
Raquel E GurDepartment of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Theodore D SatterthwaiteDepartment of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Daniel H WolfDepartment of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.ORCID 0000-0002-9731-8781
Dani S BassettDepartment of Bioengineering, School of Engineering & Applied Science, University of Pennsylvania, Philadelphia, PA, 19104, USA. dsb@seas.upenn.edu.ORCID 0000-0002-6183-4493
University of Pennsylvania · USSanta Fe Institute · US

Funding

Longitudinal Mapping of Network Development Underlying Executive Dysfunction in AdolescenceR01MH113550 · NIMH · UNIVERSITY OF PENNSYLVANIA · PI Danielle Smith Bassett, Theodore Satterthwaite · 2018 to 2026
$6.9M
TRAINING PROGRAM IN NEUROPSYCHOPHARMACOLOGY-PREDOCTORALT32MH014654 · NIMH · UNIVERSITY OF PENNSYLVANIA · PI BERRETTINI, WADE H · 1985 to 2021
$5.0M
Reproducible imaging-based brain growth charts for psychiatryR01MH120482 · NIMH · UNIVERSITY OF PENNSYLVANIA · PI MILHAM, MICHAEL PETER, SATTERTHWAITE, THEODORE · 2019 to 2023
$3.5M
Network Control and Functional Context: Mechanisms for TMS ResponseRF1MH116920 · NIMH · UNIVERSITY OF PENNSYLVANIA · PI BASSETT, DANIELLE SMITH, OATHES, DESMOND · 2018 to 2018
$2.8M
Person-specific dynamic networks of nicotine withdrawal: implications for smoking cessationK01DA047417 · NIDA · UNIVERSITY OF PENNSYLVANIA · PI LYDON, DAVID MARTIN · 2019 to 2023
$763k
Discovering prognostic neuroimaging biomarkers of the psychosis spectrum using network control theoryR00MH127296 · NIMH · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI PARKES, LINDEN · 2023 to 2025
$747k
Brain iron as a neurodevelopmental mechanism for transdianostic executive dysfunctionK99MH127293 · NIMH · UNIVERSITY OF PENNSYLVANIA · PI LARSEN, BART · 2022 to 2023
$168k
Discovering prognostic neuroimaging biomarkers of the psychosis spectrum using network control theoryK99MH127296 · NIMH · UNIVERSITY OF PENNSYLVANIA · PI PARKES, LINDEN · 2021 to 2022
$146k
Structural constraints on large-scale brain activity in psychosis associated with chromosome 22q11.2 deletion syndromeF30MH118871 · NIMH · UNIVERSITY OF PENNSYLVANIA · PI CORNBLATH, ELI · 2018 to 2021
$133k
NIDA NIH HHS K01 DA047417NIMH NIH HHS F30 MH118871NIMH NIH HHS K99 MH127293NIMH NIH HHS K99 MH127296NIMH NIH HHS R00 MH127296NIMH NIH HHS R01 MH113550NIMH NIH HHS R01 MH120482NIMH NIH HHS RF1 MH116920NIMH NIH HHS T32 MH014654
6 · The paper itself

Abstract

Schizophrenia is marked by deficits in facial affect processing associated with abnormalities in GABAergic circuitry, deficits also found in first-degree relatives. Facial affect processing involves a distributed network of brain regions including limbic regions like amygdala and visual processing areas like fusiform cortex. Pharmacological modulation of GABAergic circuitry using benzodiazepines like alprazolam can be useful for studying this facial affect processing network and associated GABAergic abnormalities in schizophrenia. Here, we use pharmacological modulation and computational modeling to study the contribution of GABAergic abnormalities toward emotion processing deficits in schizophrenia. Specifically, we apply principles from network control theory to model persistence energy - the control energy required to maintain brain activation states - during emotion identification and recall tasks, with and without administration of alprazolam, in a sample of first-degree relatives and healthy controls. Here, persistence energy quantifies the magnitude of theoretical external inputs during the task. We find that alprazolam increases persistence energy in relatives but not in controls during threatening face processing, suggesting a compensatory mechanism given the relative absence of behavioral abnormalities in this sample of unaffected relatives. Further, we demonstrate that regions in the fusiform and occipital cortices are important for facilitating state transitions during facial affect processing. Finally, we uncover spatial relationships (i) between regional variation in differential control energy (alprazolam versus placebo) and (ii) both serotonin and dopamine neurotransmitter systems, indicating that alprazolam may exert its effects by altering neuromodulatory systems. Together, these findings provide a new perspective on the distributed emotion processing network and the effect of GABAergic modulation on this network, in addition to identifying an association between schizophrenia risk and abnormal GABAergic effects on persistence energy during threat processing.

Indexed as

SchizophreniaAlprazolamAmygdalaBrainBrain MappingEmotionsHumansMagnetic Resonance ImagingAlprazolam

Identifiers

PMID37353585
PMCPMC10618098
OpenAlexW4381799563

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.